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The extracellular matrix molecule tenascin-C (TNC) is
a major component of the cancer-specific matrix,
and high TNC expression is linked to poor prognosis
in several cancers. To provide a comprehensive un-
derstanding of TNC’s functions in cancer, we estab-
lished an immune-competent transgenic mouse
model of pancreatic b-cell carcinogenesis with
varying levels of TNC expression and compared
stochastic neuroendocrine tumor formation in abun-
dance or absence of TNC. We show that TNC
promotes tumor cell survival, the angiogenic switch,
more and leaky vessels, carcinoma progression, and
lung micrometastasis. TNC downregulates Dick-
kopf-1 (DKK1) promoter activity through the blocking
of actin stress fiber formation, activates Wnt
signaling, and induces Wnt target genes in tumor
and endothelial cells. Our results implicate DKK1
downregulation as an important mechanism underly-
ing TNC-enhanced tumor progression through the
provision of a proangiogenic tumor microenvi-
ronment.INTRODUCTION
Manifestation of cancer requires many steps in which the micro-
environment plays an essential role (Bissell and Labarge, 2005).
A group of tumor cells with oncogenic mutations does not readily
cause cancer, a phenomenon known as tumor dormancy
(Aguirre-Ghiso, 2007). Angiogenesis presents an important
step in awakening quiescent tumors and in driving their develop-
ment into metastatic cancer (Almog, 2010). Tumor cells secrete
soluble factors that attract endothelial cells (Kerbel, 2008). In
addition, the extracellular matrix (ECM) constitutes a major frac-
tion of cancer tissue and contributes to tumor angiogenesis and
metastasis (Lu et al., 2012). An important component of the
tumor-specific ECM is tenascin-C (TNC). TNC is known to pro-
mote malignant tumor progression and lung metastasis; yet,
the underlying mechanisms are poorly understood (Midwood
et al., 2011).
Because no stochastic and immune-competent in vivo model
existed that would recapitulate the roles of TNC in tumor pro-
gression, we generated mouse lines with different expression
levels of TNC (overexpression, wild-type, knockout) in the Rip1-
Tag2 (RT2) model of pancreatic b-cell carcinogenesis (Hanahan,
1985). This model recapitulates multistage tumorigenesis as
observed in most human cancers (Nevins, 2001; Pipas and Lev-
ine, 2001).Cell Reports 5, 1–11, October 31, 2013 ª2013 The Authors 1
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tumorigenesis including the angiogenic switch and lung micro-
metastasis. We provide a mechanistic basis showing that TNC
downregulates expression of the soluble Wnt inhibitor Dick-
kopf-1 (DKK1) (Glinka et al., 1998) by blocking actin stress fiber
formation and induces canonical Wnt signaling in tumor and
endothelial cells. Our data suggest that DKK1 downregulation
by TNC in tumor and stromal cells may provide a tumorigenesis
signaling promoting microenvironment. Given that Wnt signaling
is a crucial pathway driving angiogenesis and is activated by
TNC, this pathway may play an important role in promoting
tumor angiogenesis and metastasis by TNC. Thus, targeting
TNC or its associated signaling pathways may represent a strat-
egy to counteract tumor progression.
RESULTS
Tenascin-C Promotes TumorCell Survival, Proliferation,
and Invasiveness
To address whether TNC potentially plays a role in the RT2
model (Hanahan, 1985), we determined TNC expression during
RT2 tumorigenesis by immunofluorescencemicroscopy analysis
(immunofluorescence [IF]). In normal pancreatic islets, TNC
expression was undetectable, whereas a large fraction of hyper-
plastic and almost all angiogenic and tumorigenic islets ex-
pressed TNC (Figure S1A), suggesting a potential role of TNC
during RT2 tumor progression. Therefore, we generated RT2
mice with overexpression of TNC (RT2/TNC) and a lack of TNC
(RT2/TNCKO) (Figures S1B–S1G).
We performed tissue analysis to address whether ectopically
expressed TNC had an effect on cell proliferation. We quantified
the proportion of cells positive for phosphohistone-H3 by IF
(Figure S2A) and observed that tumors of RT2/TNC mice ex-
hibited 1.4-fold more proliferating cells than those from RT2
mice (Figure 1A) with a significant difference in hyperplastic is-
lets (Figure S2C). Surprisingly, a similar difference was also
seen in RT2/TNCKO tumors (Figures 1B and S2D). We also
investigated a potential impact of ectopically expressed TNC
on apoptosis by staining for cleaved caspase-3 (Figure S2B).
RT2/TNC tumors exhibited 2.8-fold less apoptotic cells than
RT2 wild-type tumors (Figures 1C and S2E). In contrast,
apoptosis was unchanged in RT2/TNCKO tumors in comparison
to RT2 controls (Figures 1D and S2F). However, no difference
was seen in tumor multiplicity or tumor volume between geno-
types (Figures S2G and S2H). Interestingly, upon tumor grading
we observed that the frequency of carcinomas and the ratio of
carcinomas over adenomas were higher in RT2/TNC mice
(1.8) than in RT2 controls (0.8) (Figure 1E; Table S1). We
conclude that transgenic TNC increases proliferation and sur-
vival in RT2/TNC mice and more importantly promotes tumor
progression.
Tenascin-C Promotes the Angiogenic Switch and the
Formation of Leaky and Abnormal Tumor Vessels
To address whether TNC has an effect on RT2 tumor angiogen-
esis, we isolated islets at the age of 8weekswhen the angiogenic
switch takes place in a subset of neoplastic islets (Hanahan et al.,
1996; Parangi et al., 1996) (Figure S2I). We noticed that the num-2 Cell Reports 5, 1–11, October 31, 2013 ª2013 The Authorsber of angiogenic islets was 2.4-fold higher in RT2/TNC and 2.9-
fold lower in RT2/TNCKO mice in comparison to RT2 littermates
(Figures 1F and 1G; Table S2). By quantification of CD31-posi-
tive endothelial cells (Figure S2J) in tumor sections of 12-
week-old RT2 mice, we observed that the abundance of blood
vessels was 2.6-fold higher and 1.6-fold lower in tumors of
RT2/TNC and RT2/TNCKO mice, respectively, than in RT2 con-
trols (Figures 1H and 1I).
We next addressed the question of a potential impact of TNC
on vessel anatomy by scanning electron microscopy in Mercox
corrosion casts of the tumor vasculature of multiple tumors of
RT2 and RT2/TNC mice. Using this descriptive approach, we
observed a highly aberrant vessel phenotype in some RT2/
TNC tumors that has not been seen in RT2 tumors. These ves-
sels were irregularly shaped, wider, discontinued, and bifurcated
(see arrows), reminiscent of high vessel branching and/or
leakage (Figures 1J and S2K). Because this approach is not suit-
able for quantitative determinations, we then studied vessel
lining by pericytes using NG2 staining as readout for vessel
functionality and maturation (Figure S2L). Despite more abun-
dant pericytes in RT2/TNC tumors (Figure S2M), quantification
of combined NG2 and CD31 staining signals revealed a 23.7%
reduced ratio of NG2 over CD31 in RT2/TNC tumors (Figure 1K),
which is indicative of a reduced pericyte coverage of vessels
(Song et al., 2005). Finally, we assessed vessel functionality by
analyzing fibrinogen (FBG) leakage in tumors upon PBS perfu-
sion of tumor vessels followed by FBG staining (Huijbers et al.,
2010) (Figure S2N).Whereas FBG leakage was slightly increased
(close to significance, p = 0.064) in RT2/TNC over control tumors
(Figures 1L and S2O), this analysis revealed a 1.7-fold signifi-
cantly reduced FBG staining in RT2/TNCKO tumors over RT2
wild-type tumors (Figures 1M and S2P).
Altogether, our results suggest that, whereas TNC promotes
the angiogenic switch and increases tumor blood vessel density,
it decreases vessel coverage by pericytes and increases
leakage, thus perturbing tumor vessel functionality.
Tenascin-C Increases Lung Micrometastasis
In a C57Bl/6 background, RT2 mice do not exhibit macroscopi-
cally visible metastasis. To address whether TNC had an effect
on micrometastasis formation, we determined expression of
insulin (as tumor cell-specific marker) in liver and lung tissue of
tumor-bearing mice. Upon tissue staining, we detected cohorts
of insulinoma cells within liver and lung tissue confirming their
metastatic nature (Figures 2A and S3A). Hematoxylin and eosin
(H&E) staining revealed their parenchymal localization. In a
subset of mice, we compared quantification of insulin by im-
munostaining and quantitative RT-PCR (qRT-PCR). This showed
a good correlation between both methods and indicates that
quantification by qRT-PCR reflects parenchymal localization of
micrometastasis rather than circulating tumor cells. We then
analyzed a larger sample size of liver and lung tissue by qRT-
PCR. Although we did not observe differences in liver tissue
between genotypes (Figures S3B and S3C), insulinmRNA levels
in lungs of RT2/TNC mice were 5.4-fold higher in comparison
to lungs of RT2 controls (Figure 2B). Moreover, we observed
28.3-fold lower insulin mRNA levels in lungs of mice lacking
TNC in comparison to control littermates carrying one TNC allele
Figure 1. TNC Enhances Proliferation, Survival, and Tumor Progression in RT2 Tumors
(A and B) Quantification of proliferating cells in tumor sections as PH3-positive nuclei in 12-week-old mice. (A) RT2 (n = 9 mice, n = 150 islets), RT2/TNC (n = 8,
n = 140). (B) RT2 (n = 6, n = 131) and RT2/TNCKO (n = 6, n = 137).
(C and D) Quantification of apoptotic cells as cleaved caspase-3-positive cells in tumor sections of 12-week-old mice. (C) RT2 (n = 6mice, n = 84 islets), RT2/TNC
(n = 8, n = 123). (D) RT2 (n = 4, n = 95) and RT2/TNCKO (n = 4, n = 83).
(E) Tumor grading into adenoma or invasive carcinoma (H&E-stained tumor sections) of RT2 tumors (n = 26 mice, 78 adenomas, 79 carcinomas) and RT2/TNC
(n = 22, 44 adenomas, 76 carcinomas). See Table S1.
(F and G) Number of angiogenic islets per mouse normalized to RT2 controls. See Table S2.
(H and I) Tumor blood vessel quantification upon CD31 staining of tumor sections from 12-week-old mice as CD31-positive area fraction per tumor normalized to
RT2 controls. (H) RT2 (n = 6 mice, n = 34 tumors, 203 images) and RT2/TNC (n = 4, n = 17, 106 images). (I) RT2 (n = 3, n = 71) and RT2/TNCKO (n = 3, n = 111).
(J) Morphology of the tumor vasculature in Mercox perfusion casts from 12-week-old RT2 and RT2/TNC mice. Arrows point at break point, branching, and
constriction. Scale bars, 50 mm.
(K) Pericyte coverage of tumor blood vessels upon quantification of the ratio of NG2 over CD31 staining signals. RT2 (n = 6 mice, n = 155 tumors) and RT2/TNC
(n = 8, n = 204).
(L andM) Quantification of tumor blood vessel leakage upon fibrinogen staining of tumor sections from 12-week-old mice as fibrinogen-positive area fraction per
tumor. (L) RT2 (n = 5mice, n = 62 tumors) and RT2/TNC (n = 3, n = 50). (M) RT2 (n = 4, n = 60) and RT2/TNCKO (n = 5, n = 125). Error bars represent SEM. *p < 0.05.
See also Figures S1 and S2 and Tables S1 and S2.
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formation.
TNC Expression Correlates with Low Dkk1 Levels and
Increases Wnt Target Gene Expression
Because we had noticed downregulation of the Wnt pathway
inhibitor DKK1 in T98G glioblastoma cells cultivated on a TNC-
containing substratum (Ruiz et al., 2004), we assessed a poten-tial impact of TNC on Dkk1 expression in tumors of the different
RT2 genotypes. By qRT-PCR, we noticed that 12 times more
RT2/TNC tumors (46.1%) lacked Dkk1 expression as compared
to RT2 controls (3.7%) (Figure 3A). In RT2/TNC tumors with
detectable Dkk1 expression, the levels were 16.1-fold reduced
in comparison to RT2 controls (Figure 3B). In contrast, Dkk1
levels were 2.6-fold higher in tumors lacking TNC as compared
to control tumors with one TNC allele (Figure 3C). These obser-
vations demonstrate an inverse correlation between TNC andCell Reports 5, 1–11, October 31, 2013 ª2013 The Authors 3
Figure 2. Lung Micrometastasis in RT2 Mice
Insulin expression in a lung RT2 micrometastasis (A) and quantification by
qRT-PCR (B and C). (A) Detection of metastasized insulin-positive tumor cells
in lung parenchyma (RT2 mouse) by immunostaining (upper panel) and H&E
staining (adjacent section, lower panel). Scale bar 50 mm. Detection of insulin
expression in RT2 (9/24) and RT2/TNC mice (11/24) (B) and in RT2/TNC+/
(8/13) and RT2/TNCKO littermates (4/13) (C). Error bars represent SEM. *p <
0.05. See also Figure S3.
Figure 3. Dkk1 Expression in RT2 Tumors
(A) Tumors were stratified according to Dkk1 levels, as Dkk1 expressing
(Dkk1+) or not expressing (Dkk1). Dkk1was found to be expressed in 26 of 27
RT2 tumors and in 7 of 13 RT2/TNC tumors. Difference between genotypes,
p < 0.05.
(B) Dkk1 expression was largely reduced in those RT2/TNC tumors with
detectable Dkk1 expression. Axin2 expression was enhanced in RT2/TNC
tumors.
(C) In RT2/TNCKO tumors (15 of 24 tumors were Dkk1 positive) Dkk1
expression was higher compared to RT2/TNC+/ tumors (16 of 23 tumors were
Dkk1 positive). Axin2 expression was not changed.
(A–C) Dkk1 and Axin2 expression was analyzed by qRT-PCR.
(A–D) Wnt target gene expression in all RT2/TNC and RT2/TNCKO tumors
(A–C) or in small differentiated tumors (D), see Table S3. Error bars represent
SEM. *p < 0.05.
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signaling through Dkk1 repression. To address this possibility,
we determined the expression of Wnt target genes by qRT-
PCR. We observed an increased expression of the bona fide
Wnt signaling target Axin2 (1.4-fold) in RT2/TNC tumors (Fig-
ure 3B), whereas its expression was unchanged in RT2/TNCKO
tumors (Figure 3C). This result suggested that ectopic TNC
expression induced Wnt signaling, prompting us to analyze
expression of other Wnt target genes. Indeed, other Wnt targets
such as Cyclin D1 (2.0-fold), CD44 (2.0-fold), and Slug (1.8-fold)
were upregulated in small differentiated tumors of RT2/TNC
mice (Figure 3D; Table S3). These results suggest that TNC
may contribute to Wnt signaling activation in RT2/TNC tumors
through downregulation of the inhibitor Dkk1.
Wnt Activation and DKK1 Inhibition by TNC in Cultured
Tumor and Stromal Cells
We then designed in vitro experiments to evaluate a potential
Wnt activation by TNC involving DKK1. We used a Wnt reporter
(TOPFlash) assay where the expression of the luciferase gene is
driven by a promoter containing TCF/LEF binding sites. Upon
growth of Wnt-3A-stimulated osteosarcoma KRIB cells on a
TNC-containing substratum, we observed a 3.5-fold increased4 Cell Reports 5, 1–11, October 31, 2013 ª2013 The AuthorsWnt reporter activity (Figure 4A) and a 2.0-fold increased expres-
sion of AXIN2 (Figure 4B), demonstrating that TNC activates the
Wnt pathway.
Next, we determined whether TNC affects secretion of soluble
factors regulating Wnt signaling in KRIB cells. Therefore, we
measured Wnt reporter activity of Wnt-3A-stimulated KRIB cells
upon incubation with conditioned medium (CM) from the same
cells previously grown on fibronectin (FN) or FN/TNC and
observed that, indeed, Wnt activity was higher with CM from
cells cultured in the presence of TNC (Figure 4C). These results
suggest that TNC activates Wnt signaling through modulating
the secretion of activators or inhibitors of the Wnt pathway.
To address whether Wnt inhibitors are regulated by TNC, we
investigated their expression by qRT-PCR in cells grown on
FN/TNC and FN. Although some inhibitors (DKK4 and SFRP2)
Figure 4. TNC Leads to DKK1 Downregulation and Wnt Signaling Activation in Tumor Cells and Endothelial Cells
(A–C) Enhanced Wnt signaling in Wnt-3A-treated KRIB cells by TNC. TOPFlash activity of cells grown on FN or FN/TNC for 48 hr (A) or treated for 48 hr with Wnt-
3A CM and CM of cells grown on FN or FN/TNC (C). (B) AXIN2 mRNA levels (qRT-PCR, 5 hr).
(D)DKK1 expression (qRT-PCR, 24 hr) in the indicated tumor cell lines (KRIB, T98G, MDA-MB-435 [MDA], MCF-7, and Caco2) on FN/TNC is represented relative
to its expression on FN.
(E) Cell autonomous impact of low (knockdown) and high (overexpression) DKK1 on Wnt signaling as analyzed by TOPFlash activity after 48 hr.
(F) Repression of TNC-mediated Wnt signaling activation by Dkk1. TOPFlash luciferase activity was performed as in (A) except the addition of CM from KRIB
control or Dkk1-overexpressing cells after 5 hr of cell seeding on the indicated substrata. Note that the TNC-containing substratum still induced Wnt signaling
activity in presence of Dkk1-containing CM, but to a lesser extent (1.8-fold) than in the control conditions (3.1-fold).
(G–I) DKK1 and Axin2 mRNA levels in pericytes (G and H) and two human colorectal-cancer-derived CAF primary lines (I) seeded on FN or FN/TNC (5 hr). TNC
leads to downregulation of DKK1 in pericytes and CAFs (G and I), but AXIN2 expression remains unchanged in pericytes (H).
(J–L) EnhancedWnt signaling by TNC inHUVECs. qRT-PCR for DKK1 and AXIN2 (5 hr) (J and L) andDKK1 immunoblotting (24 hr) (K). Data from three independent
experiments (except D: MCF-7 and Caco2 cell lines, one and two experiments, respectively; and I: two experiments) are shown as mean ± SEM. *p < 0.05.
See also Figure S4.
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on the expression of other analyzed Wnt inhibitors (DKK2,
DKK3, SFRP1, SFRP3, SFRP4) in KRIB, T98G, andMDA-MB435
cells (Figure S4A). In contrast, we observed a robust downregu-
lation of DKK1 in all five analyzed tumor cell lines of different
origin after 24 hr on the TNC-containing substratum (Figures
4D and S4A). DKK1 downregulation was observed at both
RNA and protein levels, with a fast (5 hr) and long-lasting (up to
12 days) effect in T98G cells (Figures S4B and S4C).To determine whether modulation of DKK1 expression
contributes to TNC-dependent Wnt signaling in KRIB cells,
TOPFlash activity was measured upon overexpression and
knockdown of DKK1, respectively (Figures S4D–S4G). Indeed,
activity of the Wnt signaling reporter was DKK1 dependent
because it was increased upon DKK1 knockdown and
decreased upon Dkk1 overexpression (Figure 4E) and was
repressed by Dkk1-containing CM in a dose-dependent manner
(Figure S4H). When KRIB cells were incubated with Dkk1 CM onCell Reports 5, 1–11, October 31, 2013 ª2013 The Authors 5
Figure 5. Mechanism of DKK1 Downregulation
(A) Reduced DKK1 promoter activity by TNC. DKK1 promoter driven luciferase activity in T98G cells is shown upon growth for 48 hr on the indicated substrata.
(B and E) Phalloidin (red) and vinculin (green) stainings of serum-starved T98G cells upon CTR, CD (2 mM), or LB (5 mM) treatment for 3 hr (B). Nuclei are stained in
blue (DAPI). Scale bar 20 mm.
(C and D) DKK1 mRNA levels in serum-starved T98G upon LB (5 mM, 3 hr) (C) or CD (2 mM, 3 hr) (D) treatment.
(E) IF staining of T98G cells upon control or LPA (30 mM) treatment. Serum-starved T98G were plated on fibronectin (FN) or fibronectin/tenascin-C (FN/TNC), and
after 1 hr LPAwas added for 4 hr. Although cells are poorly spread under control conditions on FN/TNC (no actin stress fibers, few focal adhesions), LPA treatment
restored cell spreading associated with the formation of focal adhesions and actin stress fibers. Scale bar, 20 mm.
(F) DKK1 mRNA expression determined by qRT-PCR upon treatment with 30 mM LPA. LPA restores DKK1 expression on FN/TNC.
(G–I)DKK1mRNA expression determined by qRT-PCR upon ectopic expression of chicken syndesmos (G) andmouse TPM1 (H) or upon knockdown of TPM1 (I).
Syndesmos or TPM1 overexpression induces DKK1 mRNA expression, whereas TPM1 knockdown leads to DKK1 downregulation.
Data are shown as mean ± SEM. *p < 0.05. See also Figure S5.
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(Figure 4F), suggesting that TNC-induced repression of DKK1
facilitates Wnt pathway activation.
Next, we determined whether stromal cells also downregu-
lated DKK1 on a TNC substratum. Therefore, DKK1 expression
was determined in two monocytic/macrophage cell lines, pri-
mary human brain pericytes, two colorectal cancer derived
carcinoma associated fibroblasts (CT5.1, CT14), and human
umbilical vein endothelial cells (HUVECs) upon growth on FN/
TNC and FN. We noticed that in contrast to the two macrophage
lines that did not at all express DKK1, pericytes (5-fold), CAFs
(3.0- and 1.6-fold), and HUVECs (2.2-fold) significantly downre-
gulated DKK1 mRNA (Figures 4G, 4I, and 4J) and protein (Fig-
ure 4K) on a TNC substratum. Whereas Axin2 expression was
not affected in pericytes (Figure 4H), Axin2 mRNA was 2.3-fold
increased in HUVECs on FN/TNC in comparison to FN (Fig-
ure 4L). Altogether, our results show that TNC induces downre-
gulation of DKK1 in tumor and stromal cells and activates Wnt
signaling in tumor and endothelial cells.
Mechanism of DKK1 Downregulation by TNC
First, we determined whether DKK1 mRNA stability is substra-
tum dependent. Therefore, T98G cells were treated with the6 Cell Reports 5, 1–11, October 31, 2013 ª2013 The AuthorsRNA polymerase II inhibitor Actinomycin D, but DKK1 mRNA
levels were equally low in cells on FN and FN/TNC, suggesting
that DKK1 is not regulated by mRNA stabilization (Figure S5A).
Next, we addressed whether TNC downregulates DKK1 at tran-
scriptional level. Therefore, we performed reporter assays by
measuring luciferase activity under control of a 3.2 kbDKK1 pro-
moter sequence. Indeed, we observed a 2.5-fold reduced DKK1
promoter activity in cells grown for 48 hr on a TNC-containing
substratum (Figure 5A).
Because TNC blocks actin stress fiber formation (Huang et al.,
2001; Midwood et al., 2004; Murphy-Ullrich et al., 1991; Orend et
al., 2003), we investigated whether disruption of the actin cyto-
skeleton has an impact on DKK1 mRNA levels. Treatment with
Latrunculin B (LB) andCytochalasin D (CD) disrupted actin stress
fibers and focal adhesions and, importantly, reduced DKK1
expression (Figures 5B–5D). To address the converse whether
more actin stress fibers stimulate DKK1 expression, we treated
KRIB and T98G cells with lysophosphatidic acid (LPA) and
observed an increased and dose-dependent DKK1 mRNA
expression similar to serum response factor (SRF), a known actin
stress fiber-regulated gene (Gineitis and Treisman, 2001;
Spencer and Misra, 1999) (Figures S5B–S5F). Moreover, LPA
(30 mM) restored cell spreading, actin stress fibers, and focal
Figure 6. Dkk1 Overexpression Inhibits
Osteosarcoma Growth and Angiogenesis
(A)Mean tumor volume of control (CTR, n = 10) and
Dkk1-overexpressing (n = 9) KRIB tumors upon
subcutaneous injection of the corresponding cells
into nude mice.
(B) Representative tumor images.
(C) Tumor microvessel density, as determined by
CD31 staining and quantification, was 2.2-fold
reduced in KRIB:Dkk1 tumors (n = 8) as compared
to control KRIB tumors (n = 10).
Error bars represent SEM. *p < 0.05. See also
Figure S6.
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importantly largely restored DKK1 levels on this substratum to
that on FN (Figures 5E and 5F). Because LPA can trigger RhoA
signaling (Mills and Moolenaar, 2003), and RhoA expression
(Lange et al., 2007) and function (Wenk et al., 2000) are impaired
by TNC, we determined whether overexpression of a constitu-
tively active (CA) RhoA molecule impacts on DKK1 expression.
Whereas, CA-RhoA increased SRF target gene expression (Fig-
ures S5G–S5J), it did not alter DKK1 expression (Figures S5K
and S5L), suggesting that LPA triggers DKK1 expression by a
RhoA-independent pathway.
Because tropomyosin-1 (TPM1) and syndesmos overexpres-
sion bypass the cell adhesion blocking and actin stress-fiber-
disrupting effect of TNC on a FN/TNC substratum (Lange et al.,
2008), we determinedwhether ectopic expression of syndesmos
and TPM1 have an impact on DKK1 expression. Whereas
shTPM1 blocked DKK1 expression, overexpression of syndes-
mos and TPM1 increased DKK1 mRNA levels to 4.7- and 3.6-
fold, respectively (Figures 5G–5I and S5M–S5P).
Altogether, these results demonstrated that DKK1 expression
is regulated at the promoter level and that actin stress fibers and
focal adhesion signaling drive DKK1 transcription independently
of RhoA. We conclude that TNC downregulates DKK1 transcrip-
tion by blocking focal adhesion and actin stress fiber formation.
Repression of Tumor Angiogenesis by DKK1
As we observed that TNC promotes tumor angiogenesis and
downregulates DKK1 expression, we addressed whether
DKK1 impacts on tumor angiogenesis in xenografted tumors of
KRIB cells with different DKK1 levels. We found that upon
Dkk1 overexpression (Figure S6A) tumors were significantly
smaller (Figure 6A) and pale (Figure 6B). Quantification of micro-
vessel density upon CD31 staining revealed that Dkk1-overex-
pressing tumors were less vascularized (Figure 6C), suggesting
that Dkk1 overexpression impaired tumor angiogenesis. In addi-
tion, conditioned medium from KRIB cells overexpressing Dkk1
inhibited HUVEC tubulogenesis on Matrigel in vitro (Figure S6D).
We addressed whether Dkk1 potentially had an impact on tumor
growth through inhibiting tumor cell proliferation and found no
statistically significant difference in proliferation in cultured cells
or in the tumorswith elevatedDkk1 levels (Figures S6B andS6C).Cell Reports 5, 1–1Because Dkk1 influenced proliferation of
tumor cells neither in vitro nor in vivo,
our data suggest that Dkk1 overexpres-sion impairs angiogenesis and thereby inhibits KRIB tumor
growth. Because DKK1 blocks angiogenesis in a VEGFA context
(Min et al., 2011), we investigated whether full-length TNC binds
VEGFA. Indeed, by surface plasmon resonance we observed a
dose-dependent binding of VEGFA to TNC (Figure S7), extend-
ing data on binding of VEGFA to the fifth FNIII domain in TNC
(De Laporte et al., 2013) by providing a Kd of 2.73 10
7 M, which
is in the range of a VEGFA/glycosaminoglycan interaction (2.43
108 M) (Wu et al., 2009).
TNC Expression in Human Insulinomas
As we demonstrated a tumor-promoting effect of TNC in the
murine RT2 insulinoma model, we assessed a potential clinical
relevance by determining TNC expression in human insulinomas
using qRT-PCR and immunohistochemical staining of patient
tumor tissue. Of note, insulinomas are rare and most are benign,
yet a few (10%–15%)metastasize to lymph nodes and liver (Metz
and Jensen, 2008). At RNA level, we found that TNC expression
was detectable in all analyzed human insulinomas (Figure 7A).
Most importantly, we observed the highest TNC expression
levels (3/14) in tumors from patients with metastasis to liver or
lymph nodes (Figures 7A and 7B), suggesting that a high TNC
expression correlates with metastasis formation in human
insulinomas.
DISCUSSION
We have used the RT2 model of multistage pancreatic b-cell
tumorigenesis with abundant and no TNC expression to obtain
a better understanding of TNC contribution to tumor progression
and we have observed multiple effects. Enhanced TNC levels in
TNC transgenic RT2mice correlate with an increase in tumor cell
proliferation and survival, carcinoma formation, angiogenesis,
and lung micrometastasis. On the contrary, the absence of
TNC results in reduced angiogenesis and lung micrometastasis.
These results confirm a crucial role of TNC in tumor progression
as has been suspected in human cancer.
There is much evidence for an important role of TNC in pro-
moting tumor angiogenesis (Midwood et al., 2011). However,
despite the fact that TNC has been extensively investigated for
almost three decades (Chiquet-Ehrismann et al., 1986), it is not1, October 31, 2013 ª2013 The Authors 7
Figure 7. TNC Expression Correlates with Metastasis Formation in
Human Insulinomas
(A) TNCmRNA expression was determined by qRT-PCR in two patient groups
(group 1, Munich cohort; group 2, Strasbourg cohort) and is displayed as
relative expression upon normalization toGAPDH. Upon combining data of the
two groups, TNC expression in patients with metastasis is increased over that
in patients without metastasis (p < 0.05).
(B) TNC expression was determined by IHC in all tumors of the two groups of
insulinomas. Representative pictures of the three metastatic and three non-
metastatic insulinomas are shown. Scale bar, 100 mm.
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level. Whereas TNC can have stimulatory effects on endothelial
cell migration, conflicting reports exist concerning its impact
on tubulogenesis. A proangiogenic effect of TNC linked to
VEGFA expression was seen in humanmelanoma xenografts im-
planted into immune-compromised mice lacking TNC (Tanaka
et al., 2004). Of note, in the RT2/TNC tumors we did not observe
an increased VEGFA expression (M.K., F.S., G.O., unpublished
data). Our study addresses the role of TNC on tumor angiogen-8 Cell Reports 5, 1–11, October 31, 2013 ª2013 The Authorsesis systematically by using a stochastic genetic tumor model
with an intact immune system. Here, we investigated the angio-
genic switch, tumor blood vessels, and their functionality. Most
importantly, our study shows that TNC promotes the angiogenic
switch, a rate-limiting step along tumor progression (Hanahan
and Folkman, 1996), and the abundance of endothelial cells.
However, TNC seems to impair vessel functionality because tu-
mor vessels of RT2/TNC mice are morphologically aberrant and
less covered by pericytes. Moreover, vessels in RT2 tumors
lacking TNC are less leaky than those with TNC, suggesting a
role of TNC in the formation of more but less functional tumor
vessels.
We have identified DKK1 as an important TNC target in RT2
tumors. Our in vivo and in vitro results suggest that TNC pro-
motes tumor progression involving DKK1 downregulation and
activation of Wnt signaling. First, the TNC copy number inversely
correlates with DKK1 expression in RT2 tumors, and a TNC sub-
stratum downregulates DKK1 expression in tumor and several
stromal cell types (CAFs, pericytes, and endothelial cells). Sec-
ond, Wnt signaling is increased by TNC in the RT2 model and
in cultured endothelial and tumor cells. Third, TNC-induced
Wnt activation is reduced in tumor cells by DKK1. Finally, down-
regulation ofDKK1 by TNCmay be a key event because no other
major Wnt inhibitor is consistently regulated by a TNC-contain-
ing substratum (our data; Ruiz et al., 2004).
Several transcriptional regulators, epigenetic silencing, and
tissue tension were shown to regulate DKK1 expression (Agui-
lera et al., 2006; Barbolina et al., 2013; Liao et al., 2008; Menezes
et al., 2012; Penda´s-Franco et al., 2008; Zhou et al., 2012). Here,
we demonstrate that TNC downregulates DKK1 expression by
promoter inhibition. Because TNC blocks actin stress fiber for-
mation (Huang et al., 2001; Midwood et al., 2004; Murphy-Ullrich
et al., 1991; van Obberghen-Schilling et al., 2011), we investi-
gated whether DKK1 expression is regulated by the actin poly-
merization state and demonstrated that TPM1 antisense and
drug-induced disruption of the actin cytoskeleton reduced
DKK1mRNA levels. On the contrary, enforcing actin polymeriza-
tion and stress fiber formation by overexpression of syndesmos,
bridging integrin a5b1 and syndecan-4 in focal adhesions (Bass
and Humphries, 2002), largely increased DKK1 expression. We
further showed that LPA rescued focal adhesion and actin stress
fiber formation and cell spreading on FN/TNC, whichwe linked to
restored DKK1 expression in a RhoA-independent manner. How
TNC downregulates DKK1 expression at promoter level is
currently unknown and requires further investigation, but it
does not appear to be exclusively dependent on the SRF cotran-
scription factor MKL1 that is regulated by actin polymerization
(Miralles et al., 2003) (A.S. and G.O., unpublished data). Previ-
ously, it was shown that a stiffened collagen substratum, impli-
cating integrin adhesion signaling (Levental et al., 2009), induces
DKK1 downregulation in several cell types including endothelial
cells (Barbolina et al., 2013). Here, we report a mechanism
whereby TNC blocks DKK1 transcription through disruption of
actin stress fibers.
The role of DKK1 in developmental and tumor angiogenesis
appears to be context dependent, because DKK1 can pro-
duce pro- and antiangiogenic effects (Aicher et al., 2008; De
Langhe et al., 2005; Min et al., 2011; Oh et al., 2012; Reis
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context seems to be particularly critical for the outcome,
because, for example, DKK1 promotes basic fibroblast-
growth-factor-induced angiogenesis (Aicher et al., 2008; Reis
et al., 2012; Smadja et al., 2010) but blocks VEGFA-induced
(Min et al., 2011) angiogenesis in Matrigel plug assays in vivo.
We here confirm that DKK1 inhibits HUVEC tubulogenesis
in vitro (Min et al., 2011) and tumor angiogenesis in an osteosar-
coma xenograft model in vivo.
Employing the RT2 model, we show that TNC promotes
metastasis formation to the lung but not to the liver. This is remi-
niscent of breast cancer where TNC is part of a gene expression
signature specifically associated with lung but not bone metas-
tasis (Minn et al., 2005), an initial observation that has been
subsequently confirmed and functionally validated using xeno-
graft models (Oskarsson et al., 2011; Tavazoie et al., 2008).
Mechanistically, TNC expression was linked to an increased
tumor cell survival and activation of Wnt and Notch signaling,
as revealed by increased expression of Lgr5 and Msi1, respec-
tively (Oskarsson et al., 2011). Although we have shown that
Wnt signaling is activated in TNC-overexpressing RT2 tumors
and in cellular models comprising tumor and endothelial cells
in vitro, the expression of Lgr5 and of several Notch pathway
members are unaffected in the in vivo and in vitro models we
used (Table S3; F.S. andG.O., unpublished data). Multiple expla-
nations for these differences may exist, such as difference in
model systems and in organ and tissue context. We have shown
that the ectopic expression of TNC leads to DKK1 downregula-
tion andWnt signaling activation in RT2/TNC tumors as revealed
by the upregulation of other Wnt target genes, including the
prototypical Wnt target Axin2. Conversely, in RT2/TNCKO tu-
mors DKK1 levels were increased, but Axin2 expression was
unchanged. This result is in line with a previous report showing
that the Wnt pathway has minimal basal activity in pancreatic
beta tumor cells and is dispensable for RT2 tumor progression
(Herzig et al., 2007). In addition to canonical Wnt signaling, the
DKK1 receptor LRP6 was shown to promote PDGF-BB, TGF-b
and CTGF signaling in pericytes and fibroblasts. Importantly,
these signaling activities were blocked by DKK1 through binding
to LRP6 (Ren et al., 2013). We suggest that a TNC-rich matrix
induces a microenvironment with low DKK1 levels that is
susceptible to angiogenic signaling from Wnt and other path-
ways regulated by DKK1. This possibility is supported by our re-
sults that have shown an inverse correlation of TNC and DKK1
expression, promotion of the angiogenic switch by TNC, and a
strong downregulation of DKK1 by TNC in tumor and several
stromal cell types.
In the TNC transgenic RT2 model, we observed that TNC
promotes multiple early events such as proliferation and survival
in hyperplastic islets, Wnt target upregulation in small, differ-
entiated tumors, and the angiogenic switch. A major role of
TNC early in tumorigenesis combined with a less functional
vasculature may explain why macroscopically visible RT2
tumors of the different genotypes did not differ in size. A po-
tential early role of TNC in tumorigenesis has not received
much attention because cancer patient data with a correlation
of high TNC expression and malignancy (Midwood and Orend,
2009; Oskarsson et al., 2011) rather suggested a major role ofTNC in late events. In human cancer tissue, early events cannot
be easily addressed, which might explain why we did not see a
correlation of TNC and DKK1mRNA expression levels in human
cancer tissues. TNC promotes metastasis (Minn et al., 2005; Os-
karsson et al., 2011; Tavazoie et al., 2008), which has also been
recapitulated here in the RT2 model and in human insulinomas
where the highest TNC expression levels were observed in the
few available metastatic insulinomas.
In summary, we have shown that DKK1 expression is depen-
dent on actin stress fibers that are disrupted by TNC. We have
established a transgenic immune-competent tumor mouse
model that mimics the high expression of TNC observed in
human cancer. Our results prove that TNC plays crucial roles
along tumor progression by promoting early and late events.
We demonstrate that TNC levels determine the extent of tumor
cell survival, invasion, tumor angiogenesis, and metastasis.
These phenotypes appear to be linked to DKK1 downregulation
creating a proangiogenic tumor microenvironment. Finally, our
human TNC-expressing transgenic tumor mice offer a model
for human insulinoma progression and for the preclinical evalua-
tion of drugs that target human TNC.
EXPERIMENTAL PROCEDURES
Mice
Generation of transgenic RipTNC mice, breeding, genotyping, xenograft ex-
periments, and analysis of tumor material are specified in the Supplemental In-
formation. RT2mice developing pancreatic neuroendocrine tumors (Hanahan,
1985) were crossed with RipTNC (this study) or TNCKO (Forsberg et al., 1996)
mice to generate double-transgenic mice with forced expression of TNC (RT2/
TNC) or lacking TNC expression (RT2/TNCKO). Experiments comprising ani-
mals were performed according to the guidelines of INSERM and the Swiss
Federal Veterinary Office.
Histopathological Analysis of Mouse and Human Tissue
Tumor incidence per mouse was determined as the number of all visible tu-
mors with a minimal diameter of 1 mm. Tumor volume was calculated
assuming a spherical shape with formula V = 1/6 3 p 3 d3 (d = tumor diam-
eter). Pancreata, liver, and lung tissue were isolated, fixed in 4% paraformal-
dehyde (PFA) overnight followed by embedding in paraffin, fixed for 2 hr in
4% PFA, immersed in 20% sucrose overnight, and embedded in Tissue-Tek
O.C.T. (Sakura Finetek) or freshly embedded in O.C.T. and frozen on dry ice.
Histological analysis was performed on 5 mm (paraffin embedded) and 7 mm
(cryopreserved) tissue sections by staining with H&E or immunostaining. Pri-
mary antibodies were incubated overnight at 4C. Immunohistochemical
(IHC) detection was performed on paraffin-embedded tissue using Vectastain
developing system (Vector Laboratories), followed by staining with hema-
toxilin. Detection by IF was performed on fixed or fresh-frozen tissue using
fluorescein-isothiocyanate- or Cy3-coupled secondary antibodies (Jackson
ImmunoResearch Laboratories); cell nuclei were stained with DAPI. Primary
antibodies detecting the following molecules were used: phosphohistone H3
(PH3, 1:200, Upstate 06-570), cleaved caspase-3 (1:50, Cell Signaling Tech-
nology 9661), CD31 (1:50, BD Pharmingen 550274, Acris BM4086), NG2
(1:200, Millipore AB5320), insulin (1:200, Dako Cytomation A0564), glucagon
(1:1000, Sigma G2654), KI67 (1:200, clone SP6, Thermo Scientific, RM-
9106-S1), human TNC (BC-24, 1:3000, Sigma T2551), and fibrinogen (1:500,
Dako A0080). Anti-mouse TNC MTn12 (Aufderheide and Ekblom, 1988) and
anti-human TNCB28.13 antibodies (Schenk et al., 1995) were purified from hy-
bridoma culture supernatants.
Quantification of IF microscopic pictures was done using ImageJ (National
Institutes of Health) software. Staining protocols (fixation, blocking, antibody
dilution) and image acquisition setting (microscope, magnification, light inten-
sity, exposure time) were kept constant per experiment. Data were quantifiedCell Reports 5, 1–11, October 31, 2013 ª2013 The Authors 9
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analyzed DAPI-positive cell area (cleaved caspase-3, PH3, and KI67) or as
area fraction over analyzed tumor area (CD31, NG2, and fibrinogen).
Cell-Culture Experiments
Coating of cell-culture dishes with FN and TNC was performed as described
earlier (Huang et al., 2001; Lange et al., 2007). Cells were seeded on the coated
surfaces and analyzed using standard protocols as described. mRNA was ex-
tracted from paraffin-embedded tissue and analyzed by qRT-PCR.
Human Insulinomas
Tumor material was obtained from the Klinikum rechts der Isar (Munich, Ger-
many) or the Hoˆpital de Hautepierre (Strasbourg, France). Analysis of the hu-
man insulinomas had been approved by the respective ethics committees.
All samples were obtained after prior patient informed written consent. Tumor
tissue was obtained from 14 patients (group 1, Munich, and group 2, Stras-
bourg) with endocrine pancreatic cancer and was histopathologically
confirmed as insulinoma by an experienced pathologist. Presence of metas-
tasis was diagnosed in three patients (liver or lymph node n = 2, group 1; liver
and lymph node n = 1, group 2).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and three tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2013.09.014.
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Extended Experimental Procedures  
 
Generation of transgenic RipTNC mice 
The human TNC cDNA sequence (GenBank X78565.1) comprising all but AD1 and AD2 
extra domains was removed from the HxBL.pBS plasmid (Aukhil et al., 1993) and cloned 
into the Rip1 expression vector (Hanahan, 1985) for insulin promoter driven expression 
by using the intermediate pcDNA3.1/Hygro(-) vector (Figure S1B). Successful cloning 
was confirmed by restriction enzyme analysis and partial sequencing. Expression and 
secretion of TNC was determined in a RT2 cell line by immunostaining and sandwich 
ELISA. The TNC expression vector was injected into the pronucleus of fertilized oocytes 
giving rise to transgenic RipTNC mice with stable transmission and expression of the 
transgene. Transgenic mice were healthy and fertile and did not exhibit any detectable 
alterations in tissue morphology (Figure S1F) nor blood glucose homeostasis (Figure 
S1G). All experimental procedures involving mice were done according to the guidelines 
of INSERM and the Swiss Federal Veterinary Office.  
 
Generation of tumor mice with different TNC expression levels  
RT2 mice (Hanahan, 1985) were bred with RipTNC mice (three lines) or TNCKO mice 
(Forsberg et al., 1996) to generate RT2/TNC or RT2/TNCKO mice respectively, with 
different TNC expression levels (Figure S1D, E). TNC expression analysis confirmed that 
tumors of RT2/TNC mice expressed transgenic human TNC (Figure S1D), whereas those 
from RT2/TNCKO mice lacked the TNC protein (Figure S1E). Starting at the age of 10 
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weeks the drinking water was supplemented with 5% (w/v) glucose (FLUKA). Most data 
were obtained from mice in a C57Bl6 background except results in Figure 2C, Figure 3C 
and Figure S3C that were derived from RT2/TNCKO mice and littermates with one TNC 
copy (RT2/TNC+/-) in a mixed 129/Sv-C57Bl6 background. For genotyping by PCR the 
following primers were used, RipTNC (Fwd: 5’-TAA TGG GAC AAA CAG CAA AG-3’, Rev: 
5’-GAA AGA CAC CTG CCA ACA GC-3’), SV40 Tag (Fwd: 5’-GGA CAA ACC ACA ACT AGA 
ATG CAG-3’, Rev: 5’-CAG AGC AGA ATT GTG GAG TGG-3’) and TNCKO (Fwd wt: 5’-CTG 
CCA GGC ATC TTT CTA GC-3’, Fwd TNCKO: 5’-CTG CTC TTT ACT GAA GGC TC-3’, Rev: 
5’-TTC TGC AGG TTG GAG GCA AC-3’).  
 
Tumor grading  
Tumor grading was performed on H&E stained paraffin sections and classified into 
adenomas (differentiated tumor cells, encapsulated tumors) and Grade 1 carcinomas 
(differentiated tumor cells, one invasive tumor front), Grade 2 carcinomas (partially 
dedifferentiated tumor cells, more than one invasive tumor front) and Grade 3 
carcinomas (heterogeneous appearance and loss of differentiated tumor cells, many 
invasion sites). 
 
Human insulinomas 
Tumor material was obtained from the Klinikum rechts der Isar (Munich, Germany) or the 
Hôpital de Hautepierre (Strasbourg, France) with prior patient informed written consent. 
Patients underwent surgical resection at the Department of Surgery, Klinikum rechts der 
Isar, Munich, Germany (between 1991 and 2011) (Group 1) and at the Hôpital de 
Hautepierre, Strasbourg (between 1994 and 2007) (Group 2). Tissue specimens were 
transferred into liquid nitrogen and stored until further processing for mRNA extraction, 
embedded in Tissue-Tek (Sakura, Labonord) and stored at -80°C, or fixed in formalin and 
embedded in paraffin. The median age of patients from Group 1 was 52 years (35 to 82 
years, 5 male and 2 female patients) and of patients from Group 2 was 46 years (13 to 
69 years, 2 male and 5 female patients). Presence of metastasis was diagnosed in three 
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patients (liver or lymph node n = 2, Group 1; liver and lymph node n = 1, Group 2). 
Analysis by qRTPCR, IF and IHC was performed as described. 
 
Oral glucose tolerance test 
12 week old mice (14 RipTNC and 15 wildtype) were starved overnight in clean cages 
with free access to water. Tail vein blood glucose concentration was measured at time = 
0 using Glucofix sensor for Glucofix mio (A. Menarini Diagnostics). 2 mg glucose per g 
body weight was orally administered by gavage and blood glucose levels (mg/dl) were 
measured every 15 minutes for 1.5h.  
 
Perfusion, fibrinogen staining and quantification of tumor vessel leakiness 
Twelve week old mice were anesthesized by i.p. injection of pentobarbital (5%, 4µl/g 
body weight). The chest was opened and the right atrium was cut. The left heart 
ventricle was perfused with 10 ml of 4% paraformaldehyde (PFA) followed by 10 ml of 
PBS through a 23G syringe connected to a peristaltic pump at constant pressure. The 
pancreas was dissected, incubated overnight in 20% sucrose at 4°C and frozen in O.C.T. 
Seven µm sections were processed for fibrinogen and CD31 immunofluorescent staining 
as described. Fibrinogen immunoreactive areas were measured by using the ImageJ 
software and were expressed as percentage of tumor/islet total area (area fraction). 
 
Gene expression analysis of mouse tissue and human insulinomas 
Tissue from isolated tumors, liver and lung was snap frozen in liquid nitrogen. Total RNA 
extracted with NucleoSpin RNA II kit (Macherey-Nagel) from liver, KRIB tumors (1 µg), 
RT2 tumors or lung tissue (2 µg) was treated with DNase I (Invitrogen) and reverse 
transcribed (MultiScribe reverse transcriptase, Applied Biosystems). qRTPCR was done on 
cDNA diluted 1:5 (liver, lung) or 1:10 (tumors) with specific primers (Roche Probefinder 
v2.45, see primer list) on a 7500 Real Time PCR machine (Applied Biosystems) using 
SYBR green or Taqman reaction mixtures (Applied Biosystems). Data were normalized 
versus TBP (liver, lung), HMBS (KRIB tumors), GAPDH (human insulinoma) or a combined 
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value of RPL19, TBP and GAPDH (RT2 tumors). Relative expression levels (2-ΔΔct) were 
calculated for each individual sample. 
 
Isolation of pancreatic islets  
Langerhans islets were isolated from 8 week old RT2 mice by using Liberase RI (Roche) 
(RT2/TNC and RT2) and Liberase TL (Roche) (RT2/TNCKO and RT2). The pancreas was 
perfused via the bile duct with 2 ml Liberase solution (0.82 (RI), 1 (TL) Wünsch units/ml), 
collected and digested at 37°C (24 minutes (Liberase RI), 17 minutes (Liberase TL)). 
Upon recovery from the interphase of a Histopaque 1077 (Sigma)/DMEM centrifugation 
gradient (30 minutes, 1500 x g) intact islets were handpicked under a stereomicroscope 
and quantified as non-angiogenic (white) or angiogenic (red).  
 
Methylmethacrylate (Mercox) casting and SEM analysis 
Anaesthetized mice were perfused through the thoracic aorta with a 0.9% sodium 
chloride/1% heparin/1% procaine solution followed by a freshly prepared Mercox solution 
(Vilene Japan Hospital Co. Ltd.) containing 0.1 ml accelerator per 5 ml resin. After 
solidification pancreata were excised and kept for 3 weeks in 7.5% KOH for tissue 
dissolution. Casts were dehydrated in ethanol and vacuum dried. Samples were mounted 
on aluminum stubs, sputtered with gold and examined in a Philips XL-30 SFEG scan 
electron microscope.  
 
Cell culture, gene expression and immunoblotting 
Human brain vasculature pericytes (ScienCell 1200), tumor cell lines, 
monocyte/macrophage cell lines (J774.A1 and RAW264.7) and L cells (fibroblasts, control 
and overexpression of Wnt-3A) (American Type Culture Collection, Rockville, MD, 
(ATCC)) were maintained in DMEM/4.5g/l glucose/10% FCS. Cancer associated 
fibroblasts (CAF) CT5.1 and CT14 were cultured in DMEM/1g/l glucose/10% FCS. BOSC 
cells (ATCC) were maintained in DMEM/10% FCS supplemented with 1 mM sodium 
pyruvate/10 mM Hepes and, HUVEC (Promo cell, C-12203) were maintained in 
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Endothelial cell growth medium (PromoCell, C-22010). T98G:TPM1, T98G:Syndesmos 
and T98G:shTPM1 cells (Lange et al., 2008; Ruiz et al., 2004) were cultured in 
DMEM/10%FCS with 400 µg/ml G418.  
Human CAFs were isolated from colorectal adenocarcinoma resection specimens from 2 
patients that were obtained in accordance with the local ethics committee (Ghent 
University Hospital) (De Boeck et al., 2013; De Wever et al., 2004). Tissue fragments 
were cut in 1-2 mm3 pieces and transferred into a pre-scratched 6-well plate with 100 l 
FCS supplemented antibiotica DMEM. Cultures were incubated at 37°C with 10% CO2 in 
air for 24h. DMEM containing 10% FCS was added into each well. Cell outgrowth was 
observed after 3-6 days. After 15 days, adherent cells were transferred to 25 cm2 tissue 
culture flasks.  
Conditioned medium containing Wnt-3A or mDKK1 was collected from L cells 
overexpressing Wnt-3A and from KRIB cells overexpressing mDKK1, respectively after 3 
to 4 days of culture. Medium was filter-sterilized and stored at -20°C. Cells starved in 
DMEM/1% FCS (tumor cells, pericytes, CAF) or M199/1% FCS/1µg/ml hydrocortison/10 
ng/ml heparin/10 ng/ml mEGF/10 ng/ml bFGF (HUVEC) were seeded onto matrix coated 
dishes as published (Huang et al., 2001; Lange et al., 2007). Briefly, FN and TNC were 
sequentially coated in PBS/0.01% Tween-20 at 1 µg/cm2 before saturation of the non-
coated surface with 10 mg/ml BSA/PBS.  
Cells were starved overnight before treatment with 1, 10 or 30 µM LPA for 3-4h on FN or 
FN/TNC substrata (Santa Cruz, H2O), 5 µg/ml Actinomycin D for 30, 60 or 90 minutes 
(Sigma-Aldrich, DMSO), 5 µg/ml Latrunculin B for 3h (Calbiochem, DMSO) and 2 µg/ml 
Cytochalasin D four 3h (Calbiochem, DMSO). 
 
Gene expression analysis of cultured cells 
RNA was isolated (NucleoSpin RNA extraction kit, Macherey-Nagel or Trizol, Life 
Technologies) according to the manufacturer’s instructions. RNA was reverse transribed 
(MultiScribe reverse transcriptase, Applied Biosystems) and qRTPCR was done on cDNA 
diluted 1:2.5 in water with specific primers (see primer list) on a 7500 Real Time PCR 
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machine (Applied Biosystems) using SYBR green reaction mixture (Applied Biosystems). 
Data were normalized versus ß2-microglobulin expression and relative expression levels 
was calculated (2-ΔΔct).  
 
 
Immunoblotting 
For immunoblotting cells were lysed in Laemmli buffer (Laemmli, 1970). Antibodies 
against the following molecules were used: DKK1 (n-terminal, Sigma-Aldrich, D3195, 
1:1500), DKK1 (R&D, AF1096, 1:500),  6x His-tag (Abcam, ab18184, 1:1000), RhoA 
(Santa-Cruz, sc-418, 1:5000), -tubulin (CP06, Oncogene, Boston, MA, USA, 1:2000). 
Secondary antibodies were ECL horseradish peroxidase linked whole anti-rabbit (NA934V) 
and anti-mouse (NXA931) (GE Healthcare, Buckinghamshire, UK) and donkey anti-goat 
IgG (sc-2020, Santa Cruz, Biotechnology). Amersham ECL (RPN2106) or Amersham ECL-
Plus Western blotting detection system (RPN2132) (GE Healthcare, Buckinghamshire, UK) 
was used.  
 
Immunofluorescence staining of cultured cells 
Cells were fixed in 1% PFA for 10 minutes and permeabilized in PBS-Triton 0.1% for 10 
minutes. Cells were stained with anti-vinculin (Abcam; 1/50; 2h) and anti-mouse Alexa-
488 (Jackson ImmunoResearch; 1/800; 1h). For phalloidin staining cells were incubated 
for 20 minutes with phalloidin-tetramethylrhodamine B isothiocyanate (Sigma P1951; 
1/200). Nuclei were stained with DAPI (Sigma D9542).  
 
Retrovirus construction and infection, plasmid transfection and reporter assays  
For generating mDKK1 cDNA with a V5-His-tag the mDKK1 cDNA (Ruiz et al., 2004) was 
cloned into the pcDNA3.1-V5-His-TOPO vector (Invitrogen) according to the 
manufacturer’s guidelines. For generating the pQCXIP-mDKK1-V5-His vector a BamHI 
and an EcoRI site were added in pcDNA3.1-mDKK1-V5-His-TOPO plasmid before the ATG 
or the stop codon of the mouse DKK1 cDNA respectively, using the GeneEditor™ in vitro 
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site-directed mutagenesis system, with the primers 5’-GGT GGA ATT GCC CTT GGA TCC 
ACA TGA TGG TTG TGT-3’ and 5’-P-ACC ATC ACC ATT GAG AAT TCA CCC GCT GAT CAG 
CC-3’. Upon BamHI-EcoRI cleavage, the mDKK1-V5-His fragment was gel purified 
(NucleoSpin® Extract II, Machery-Nagel, France) and cloned in the BamHI-EcoRI site of 
the pQCXIP retroviral vector (Clontech, Ozyme, France) generating the pQCXIP-mDKK1-
V5-His vector. BOSC cells were transfected with the pQCXIP-mDKK1-V5-His vector or 
empty control (CTR) vector to obtain retroviruses for transduction of KRIB cells followed 
by selection with puromycin (2.5 µg/ml). Expression of mDKK1 was determined by 
qRTPCR and immunoblotting. 
 
T98G were transiently transfected (JetPEI, Polyplus, Strasbourg, France) with plasmids 
encoding RhoA wt (Addgene Plasmid 12962: pRK5-myc-RhoA-wt), RhoA-Q63L (Addgene 
Plasmid 12964: pRK5-myc-RhoA-Q63L) and RhoA-T19N (Addgene Plasmid 12963: pRK5-
myc-RhoA-T19N). Empty pCB6 plasmid was used for control transfection. 
 
Luciferase reporter assays 
For the -catenin luciferase reporter assay, cells were transiently transfected (JetPEI, 
Polyplus, Strasbourg, France) with the Super-8xTOPFlash or control Super-8xFOPFlash 
plasmids (mutant TCF/LEF binding sites) (Veeman et al., 2003) (obtained from Addgene, 
plasmids 12456 and 12457). Upon seeding for 5h on matrix coated dishes, CM containing 
Wnt-3A, mDKK1 or CTR medium was added for a total of 48h. TOPFlash luciferase activity 
was calculated after normalization to Renilla and FOPFlash activity (Dual-luciferase 
reporter assay system, Promega, Madison, WI, USA). 
 
For SRF luciferase reporter assays T98G cells were transfected with the 3DA.Luc plasmid 
(provided by Guido Posern, University Halle-Wittenberg, Halle, Germany) encoding c-fos 
derived SRF binding sites and a pRL-TK plasmid for normalization of the luciferase signal.  
 
A 3177 bp human DKK1 promoter sequence was cloned from HCT116 genomic DNA into 
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the multiple cloning site of the pGL3-basic luciferase reporter vector (Promega). Cells 
were transiently transfected with the pGL3-DKK1 promoter construct or empty pGL3-
basic vector for 40h. Luciferase activity normalized to Renilla activity is presented as the 
ratio of pGL3-DKK1 to pGL3-basic. 
 
Generation of KRIB shDKK1 cells 
For generation of KRIB shDKK1 cells, KRIB cells were infected with MISSION lentiviral 
transduction particles (SHCLNV, clone ID TRCN0000033386, Sigmal-Aldrich) or MISSION 
non-target shRNA control transduction particles (SHC002V, Sigma-Aldrich) with a MOI = 
10 and, transduced cells were selected with 10 µg/ml puromycin. 
 
Cell proliferation assay 
To determine cell proliferation, cells were plated into 96-well plates (5 x 103 cells/well in 
quadruplicate for each time point). A MTS assay was performed following manufacturer’s 
instructions (CellTiter 96® aqueous non-radioactive cell proliferation assay, Promega) 
after 24h (day 1), 48h (day 2) and 72h (day 3). Measures were normalized to the relative 
cell number on day 1. 
 
HUVEC tubulogenesis assay  
Tubulogenesis assessment was done in 15 well dishes (µ-Slide Angiogenesis, Ibidi LLC), 
using growth factor reduced Matrigel (BD Bioscience). The matrix was prepared by 
loading 10 µl of Matrigel in each well followed by solidification for 45-60 minutes at 37°C 
in a humidified incubator. HUVEC (Promocell) were trypsinized and resuspended at 
100,000 cell/ml in conditioned medium (CM) obtained from KRIB cells overexpressing 
mouse DKK1 or its respective control (CM was collected after 2 days in confluent layers 
of both KRIB cell types). 5 X 103 cells/well (50 µl) were loaded on top of the solidified 
Matrigel and was incubated for 6h at 37°C in a humidified incubator in a 5% CO2 
atmosphere. Bright field mosaic pictures were taken using a Zeiss Imager Z2 inverted 
microscope and AxioVision software (Carl Zeiss) at 5X magnification, which allowed 
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imaging of the whole well in 9 pictures. Tube-like structures (defined by the numbers of 
closed loops) were counted using the ZEN Blue software (Carl Zeiss). 3 independent 
experiments were performed with 3-5 replicates per experiment, and measures 
subsequently were averaged. 
 
Tumor xenograft experiments  
4 x 106 KRIB CTR or mDKK1 overexpressing cells were injected subcutaneously in the left 
upper back of nude mice (Charles River). After 3.5 weeks, mice were sacrificed, the 
tumor size was measured with a caliper and the tumor volume was calculated using 
formula V=(a²*b)/2, where b is the longest axis and a is the perpendicular axis to b. 
Tumor tissue was snap frozen in liquid nitrogen or directly embedded in O.C.T. and 
further analyzed by qRTPCR and immunostaining as described. 
 
VEGFA/TNC binding study 
Surface plasmon resonance binding experiments were performed on a Biacore 2000 
instrument (Biacore Inc.) at 25°C. VEGFA165 (Millipore) or TNC (Huang et al., 2001) 
were immobilized at high surface density (around 7000 resonance units) on an activated 
CM5 chip (Biacore Inc.) using a standard amine-coupling procedure according to the 
manufacturer's instruction. Soluble molecules were added at a concentration of 10 μg/ml 
in 10 mm sodium acetate, pH 5.0, and at a flow rate of 5 μl/min for 20 min before 
addition of 1 M ethanolamine. Soluble TNC (5 - 20µg in 200µl) or VEGFA165 was added 
to the chip in 10 mm MES, pH 6.0, 150 mm sodium chloride, 0.005% (v/v) surfactant 
P20, at a flow rate of 10 μl/min. A blank CM5 chip was used for background correction. 
10 mm glycine, pH 2.0, at 100 μl/min for 1 min was used to regenerate the chip surface 
between two binding experiments. A steady state condition was used to determine the 
affinity of VEGFA165 for TNC and the affinity of TNC for VEGFA165. The Dissociation 
constant (Kd) was determined using the 1:1 Langmuir association model as described by 
the manufacturer. 
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Statistical analysis and graphical representation 
Statistical analysis was performed using GraphPad Prism. For significance of an 
association (contingency) Fisher’s exact test was applied (tumor staging, gene 
expression, metastasis incidence). Statistical differences were analyzed by unpaired t-test 
(Gaussian distribution) or nonparametric Mann-Whitney test (no Gaussian distribution). 
Gaussian data sets with different variances were analyzed by unpaired t-test with Welch’s 
correction. Gaussian distribution was tested by the Shapiro-Wilk normality test. p-values 
< 0.05 were considered as statistically significant. 
 
Primer list for qRTPCR on tumor, liver and lung tissue  
Gene  Species Forward primer Reverse primer 
Axin2 mouse CTGCTGGTCAGGCAGGAG TGCCAGTTTCTTTGGCTCTT 
CD44 mouse GTCTGCATCGCGGTCAATAG GGTCTCTGATGGTTCCTTGTTC 
CyclinD1 mouse CGCACTTTCTTTCCAGAGTCA AAGGGCTTCAATCTGTTCCTG 
DKK1 mouse Taqman (ABI) Mm00438422_m1  
DKK1 mouse CCGGGAACTACTGCAAAAAT CCAAGGTTTTCAATGATGCTT 
DKK2 mouse GCCAAACTCAACTCCATCAAG TCACTGCTGCAAGGGTAGG 
Dll4 mouse AGGTGCCACTTCGGTTACAC GGGAGAGCAAATGGCTGATA 
E-Cadherin mouse CAGCCTTCTTTTCGGAAGACT GGTAGACAGCTCCCTATGACTG 
GAPDH mouse Taqman (ABI) Mm99999915_g1  
GAPDH human ATCTTCTTTTGCGTCGCCAG AATCCGTTGACTCCGACCTTC 
Hey-1 mouse CATGAAGAGAGCTCACCCAGA TTGGGGACATGGAACACAG 
HMBS human Qiagen QT00494130 (for Sybr green)  
Insulin mouse TGGCTTCTTCTACACACCCAAG ACAATGCCACGCTTCTGCC  
Insulin mouse Taqman mIns1 Mm01259683_g1  
Lgr5 mouse GGAAAGAAATGCTTTGATGGAC AGTGGGGAATTCATCAAGGTT 
RPL19 mouse ACCCTGGCCCGACGG   TACCCTTCCTCTTCCCTATGCC   
Slug mouse GAAAAGCACATTGCATCTTTTCT TGTTCCTTTGGTTGAAATGGT 
TBP mouse CCCCACAACTCTTCCATTCT   GCAGGAGTGATAGGGGTCAT  
TNC human GTCACCGTGTCAACCTGATG GTTAACGCCCTGACTGTGGT 
 
 
Primer list for qRTPCR on cultured cells 
 
Gene  Forward primer Reverse primer 
Axin2 CCACACCCTTCTCCAATCC TGCCAGTTTCTTTGGCTCTT 
DKK-1 GACCATTGACAACTACCAGCCG TACTCATCAGTGCCGCACTCCT 
DKK-2 GGCAGTAAGAAGGGCAAAAA CCTCCCAACTTCACACTCCT 
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DKK-3 GAGGACACGCAGCACAAA TGCCAGGTTCACTTCTGATG 
DKK-4 AGGAGGTGCCAGCGAGAT CATCTTCCATCGTAGTACAAACATC 
SFRP1 GCTGGAGCACGAGACCAT TGGCAGTTCTTGTTGAGCA 
SFRP2 GCTTGAGTGCGACCGTTT CAGGCTTCACATACCTTTGGA 
SFRP3/FRZB GGGCTATGAAGATGAGGAACG CTGAGTCCAAGATGACGAAGC 
SFRP4 CGATCGGTGCAAGTGTAAAA ACCACCGTTGTGACCTCATT 
SRF AGACGGGCATCATGAAGAAG TGATCATGGGCTGCAGTTT 
TPM1 CCCGTAAGCTGGTCATCATC CTTGTGTGCTCATCATTCCGA 
RhoA 1(Sauzeau 
et al., 2003)  
GCAGGTAGAGTTGGCTTTATGG CTTGTGTGCTCATCATTCCGA 
2-Microglobulin GTGGGATCGAGACATGTAAGCA AATGCGGCATCTTCAAACCT 
   
 
  
  
1, Sauzeau et al., 2003 
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Table S1 Carcinoma progression by TNC - Related to Figure 1 
 
Genotype Adenomas (%) Carcinomas (%) 
  Grade 1 Grade 2 Grade 3 Grade 1 - 3 Ca/Ad 
RT2 55.8 32.7 10.5 0.9 44.2 0.8 
RT2/TNC 35.7 39.9 21.3 3.2 64.3 1.8 
 
Numbers of adenomas and carcinomas Grade 1 to 3 in 12 week old mice. Average 
frequency of each tumor grade per mouse is displayed; 26 RT2 mice (78 adenomas, 79 
carcinomas) and 22 RT2/TNC mice (44 adenomas, 76 carcinomas). p = 0.038, Fisher‘s 
exact test. RT2/TNC mice developed 1.8-fold more carcinomas than adenomas (p = 
0.001, Student’s t-test) compared to RT2 mice (0.8-fold, p = 0.945, Student’s t-test).  
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Table S2 TNC dependent angiogenic switch - Related to Figure 1 
 
 
Genotype All islets Islets per mouse 
 A plus NA A NA A NA 
RT2 (n = 9) 826 71 755 7.9 (±2.2) 83.9 (±7.4) 
RT2/TNC (n = 7) 810 136 674 19.4 (±4.3) 96.3 (±10.0) 
RT2/TNC versus RT2 (fold)    2.46 1.15 
p-value  < 0.0001 
a
  0.0226 
b
 0.3248 
b
 
     
RT2 (n = 7) 809 255 554 36.4 (±5.0) 79.1 (±8.6) 
RT2/TNCKO (n = 7) 840 87 753 12.4 (±2.6) 107.6 (±11.8) 
RT2/TNCKO versus RT2 (fold)    - 2.94 1.36 
p-value  < 0.0001 
a
  0.0011
 c
  0.2008
 b
  
 
 
Angiogenic (A) and non-angiogenic (NA) islets were isolated from 8 week old RT2 mice 
with the indicated genotypes and were quantified (average number including SEM per 
mouse). Islets from RT2 littermates were prepared independently in both series of 
experiments. (a) Fisher’s exact test, (b) Student’s t-test, (c) Mann Whitney test. Note 
that differences between RT2 controls originate from inherent experimental conditions 
(e.g. efficiency of collagenase treatment). 
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Table S3 Gene expression analysis of RT2 and RT2/TNC tumors - Related to 
Figure 3 
 
 
Gene 
Tumor 
class 
Relative 
expression 
p-value   Gene 
Tumor 
class 
Relative 
expression 
p-value 
Axin2 All 1.35 0.008   Dll4 All 1.66 0.153 
 Small 1.30 0.034    Small 1.55 0.186 
 Small+Diff 1.27 0.055    Small+Diff 1.43 0.258 
 Big 1.49 0.194    Big 1.93 0.376 
 Big+Diff 1.18 0.571    Big+Diff 1.61 0.786 
 Diff 1.25 0.037    Diff 1.45 0.194 
CD44 All 1.64 0.225   Hey-1 All -1.27 0.134 
 Small 1.72 0.077    Small -1.02 0.911 
 Small+Diff 2.06 0.029    Small+Diff 1.03 0.843 
 Big -1.63 0.133    Big -3.08 0.019 
 Big+Diff -1.58 0.143    Big+Diff -2.67 0.036 
 Diff 1.85 0.157    Diff -1.16 0.343 
CyclinD1 All 1.45 0.166   Lgr5 All -6.81 0.931 
 Small 1.45 0.113    Small -1.72 0.477 
 Small+Diff 2.01 0.037    Small+Diff -1.73 0.340 
 Big 1.17 0.776    Big -23.06 0.279 
 Big+Diff -1.02 0.571    Big+Diff -6.74 0.786 
 Diff 1.78 0.112    Diff -2.65 0.528 
DKK1 All -16.07 0.035   Slug All 1.28 0.220 
 Small -16.34 0.062    Small 1.67 0.010 
 Small+Diff -4.13 0.043    Small+Diff 1.84 0.004 
 Big -15.49 n.a.    Big -2.56 0.081 
 Big+Diff -3.19 n.a.    Big+Diff -2.20 0.294 
 Diff -3.90 0.044    Diff 1.46 0.063 
DKK2 All -1.85 0.204       
 Small -1.46 0.551       
 Small+Diff -1.35 0.841       
 Big -3.69 0.032       
 Big+Diff -4.67 0.036       
 Diff -1.85 0.366       
 
 
 
Relative gene expression in RT2/TNC versus RT2 tumors as determined by qRTPCR. RNA 
was isolated from tumors of 14 week old RT2 (N = 11 mice, n = 27 tumors) and 
RT2/TNC mice (N = 3, n = 13). Data are presented for all tumors (All) and subgroups : 
small tumors (Small : 1 – 3 mm in diameter, RT2 (n = 19), RT2/TNC (n = 10)), big 
 15 
tumors (Big : > 3 mm, RT2 (n = 8), RT2/TNC (n = 3)), differentiated tumors (Diff. : high 
expression of insulin and E-cadherin, RT2 (n = 22), RT2/TNC (n = 13)), small and 
differentiated tumors (Small + Diff : RT2 (n = 17), RT2/TNC (n = 10)) and big and 
differentiated tumors (Big + Diff, RT2 (n = 5), RT2/TNC (n = 3)). Bold numbers 
represent statistically significant changes in relative expression, n.a., not applicable due 
to low sample number. 
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Figure S1 TNC expression in RT2 mice, TNC expression vector and impact of 
transgenic TNC on pancreatic tissue function. Related to Figure 1 
(A) TNC expression in RT2 islets determined by IF analysis (MTn12 antibody) in tissue 
sections of 12 week old RT2 mice. In contrast to the absence of TNC from normal islets 
(N < 0.2 mm diameter), TNC is expressed in 50%, 80% and 100% of hyperplastic (H, 
0.2 – 0.5 mm diameter), angiogenic (A, > 0.5 – 1 mm diameter) and tumorigenic islets 
 17 
(T, diameter above 1 mm), respectively. Right panels, dotted lines delineate the islet 
circumferences. 82 islets (N = 26, H = 34, A = 14, T = 8) of 3 RT2 mice were analyzed. 
Scale bar, 100 m. (B) Strategy for the generation of the TNC expression vector. The 
human cDNA (Gherzi et al., 1995) was removed from the HxBL-pBS plasmid (Aukhil et 
al., 1993) and cloned into the Rip1 expression vector (Hanahan, 1985) for insulin-
promoter driven expression of the transgene by using the pcDNA3.1./Hygro(-) plasmid as 
intermediate vector. The inserted human cDNA sequence comprises 45 nucleotides 
upstream of the start site and 639 nucleotides downstream of the stop signal. (C-E) TNC 
expression analysis in RipTNC (C), RT2/TNC (D) and RT2/TNCKO pancreatic tissue (E) 
by IHC (C, D), IF (E). Scale bar 100 µm. (F) No sorting difference of -glucagon and 
insulin positive - and -cells in pancreatic tissue of wildtype and RipTNC mice was 
observed as determined by IF. (G) Determination of blood glucose levels after an oral 
glucose tolerance test in 14 RipTNC and 15 wildtype mice. Average ±SEM is presented 
for each time point.  
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Figure S2. Expression analysis, islet quantification, tumor incidence and burden, 
Related to Figure 1 
(A, B, J, L, N) Expression of the indicated molecules in RT2 tumor tissue upon IF 
analysis. Scale bar 100 µm. (C, D) Quantification of proliferation according to tumor 
stage in 12 week old mice, (C) RT2, 9 mice, 99 hyperplastic (H), 37 angiogenic (A) and 
14 tumorigenic (T) islets; RT2/TNC, 8 mice, H = 71, A = 47, T = 22, (D) RT2, 6 mice, H 
= 73, A = 38, T = 20; RT2/TNCKO, 6 mice, H = 72, A = 40, T = 25. (C) In RT2/TNC 
mice a significant 1.5 - fold increase in proliferation in hyperplastic islets is observed. (D) 
a signifcant increase in proliferation in hyperplastic (1.4-fold) and angiogenic (1.6-fold) 
islets from RT2/TNCKO mice is observed. (E, F) Quantification of apoptosis in 12 week 
 19 
old mice, (E) RT2, 6 mice, H = 55, A = 19, T = 10; RT2/TNC, 8 mice, H = 59, A = 43, T 
= 21, (F) RT2, 4 mice, H = 56, A = 26, T = 13; RT2/TNCKO, 4 mice, H = 72, A = 40, T 
= 25. In hyperplastic islets of RT2/TNC mice a significant 2.9-fold decrease in apoptosis 
is observed, while no significant difference was seen in RT2/TNCKO mice. (G, H) Tumor 
incidence and burden, (G) RT2, N = 33 mice, RT2/TNC, N = 26, (H) RT2, N = 28, 
RT2/TNCKO, N = 31. Differences were not statistically significant. (I) Image of isolated 
angiogenic and non-angiogenic islets of an 8 week old RT2 mouse. Scale bar 500 µm. 
Red arrows: angiogenic islets, blue arrows: non-angiogenic islets. (K) Representative 
SEM pictures from RT2 (N = 5 mice) and RT2/TNC tumors (N = 3). Arrow points at small 
aggregated vessels. Scale bars: top panels 200 µm, bottom panels 100 µm. (M) 
Quantification of NG2, a marker for pericytes, area fraction in 12 week old RT2 (N = 6 
mice, n = 155 islets) and RT2/TNC (N = 8 mice, n = 204 islets) mice. A significant 1.2-
fold increase of NG2 area fraction is observed in RT2/TNC islets. (O, P) Quantification of 
fibrinogen, a marker of vessel leakiness; area fraction according to tumor stage in 12 
week old mice, (O) RT2, 5 mice, H = 36, A = 18, T = 8; RT2/TNC, 3 mice, H = 26, A = 
20, T = 4; (P) RT2, 4 mice, H = 35, A = 18, T = 7; RT2/TNCKO, 5 mice, H = 59, A = 47, 
T = 9. (O) In hyperplastic islets of RT2/TNC mice an increased fibrinogen leakiness is 
observed (1.5-fold, p = 0.06). (P) In hyperplastic (1.8-fold) and angiogenic islets (1.5-
fold) of RT2/TNCKO mice, a significant decrease of fibrinogen area fraction is observed. 
Error bars represent SEM and asterisks (*) indicate p values < 0.05. 
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Figure S3. Liver micrometastasis in RT2 mice, Related to Figure 2 
(A) Detection of insulin expressing tumor cells in liver tissue of a RT2 mouse by IF 
(upper panel) and H&E of a neighboring section (lower panel). Scale bar, 50 m. (B, C) 
Quantification of insulin expression in liver tissue of RT2 mice. Insulin expression was 
detected in RT2/TNC (7/24) and RT2 (6/24) (B) and RT2/TNCKO (5/10) and RT2/TNC+/- 
littermates (6/8) (C). Differences were not statistically significant. Error bars represent 
SEM.  
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Figure S4. Impact of TNC on the expression of Wnt inhibitors, DKK1 
downregulation and activation of Wnt signaling in tumor cells, Related to Figure 
4 
(A) Expression of Wnt inhibitors in T98G, KRIB and MDAMB-435 (MDA) cells as 
determined by qRTPCR upon plating on the indicated substrata for 24h (KRIB, MDAMB-
435) or 48h (T98G). There was no expression of SFRP2 nor DKK4 detectable in any of 
the cell lines and conditions tested. (B) DKK1 expression (qRTPCR) upon plating T98G 
cells on FN/TNC and FN for the indicated time. DKK1 expression on FN/TNC is 
represented relative to its expression on FN. (C) Reduced DKK1 protein levels by TNC in 
T98G or KRIB cells upon plating for the indicated time as determined by immunoblotting. 
(D, E) Reduced DKK1 expression upon shRNA mediated DKK1 knockdown as determined 
by qRTPCR (D) and immunoblotting (E) in KRIB Sh-DKK1 cells in comparison to KRIB 
Sh-control (CTR) cells. (F) Expression of murine DKK1 in control (CTR) and mDKK1 
 22 
overexpressing KRIB cells. Overexpression of murine DKK1 in KRIB:mDKK1 cells. Lysates 
of KRIB cells expressing His-tagged mDKK1 or empty vector control were analyzed by 
immunoblotting with antibodies against DKK1 or the His-tag. (G) Expression of murine 
DKK1 in the conditioned media (CM) from control (CTR) and mDKK1 overexpressing KRIB 
cells. Supernatants from the KRIB cells expressing His-tagged mDKK1 or empty vector 
control were analyzed by immunoblotting. (H) Addition of DKK1 containing CM assessed 
by immunoblotting inhibits TOPFlash activity in KRIB cells in a dose dependent manner. 
KRIB cells were plated for 48h and treated with increasing dilutions of CM from 
KRIB:mDKK1 cells. Data are derived from at least 3 independent experiments, except for 
(H). Error bars represent SEM and asterisks (*) indicate p values < 0.05. 
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Figure S5. Mechansim of DKK1 downregulation, Related to Figure 5 
(A) Serum starved T98G cells were seeded on FN or FN/TNC. After 30 minutes 5 µg/ml 
Actinomycin D was added and cells were lysed after an additional 30, 60 or 90 minutes 
for analysis of DKK1 mRNA expression. (B) Serum starved T98G cells were treated with 
the indicated concentrations of LPA. IF staining of vinculin (green) and phalloidin (red). 
(C, D) SRF and (E, F) DKK1 mRNA expression of serum starved T98G and KRIB cells 
 24 
treated with the indicated concentrations of LPA. (G-L) T98G cells were transfected with 
RhoA wt, RhoA Q63L (CA) or RhoA T19N (DN). (G, H) Overexpression of RhoA was 
validated by immunoblotting (G) and qRTPCR (H). (I, J) SRF mRNA expression (I) and 
SRF luciferase activity of T98G cells (J). (K, L) DKK1 mRNA expression analysed by 
qRTPCR of cells seeded on uncoated (K) or FN and FN/TNC coated dishes (L). (M) 
RTPCR for chicken syndesmos of T98G CTR and T98G:syndesmos cells. (N, O) TPM1 
mRNA levels analyzed by qRTPCR in T98G:TPM1 (N), T98G:shTPM1 (O) and control 
cells. (P) IF of vinculin (green) and phalloidin (red) in T98G control, T98G:TPM1, 
T98G:syndesmos and T98G:shTPM1 cells. Nuclei are stained with DAPI (blue). Error bars 
represent SEM and asterisks (*) indicate p values < 0.05. 
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Figure S6. DKK1 expression in KRIB:mDKK1 tumors and impact of DKK1 
overexpression on tumor cell proliferation and migration, Related to Figure 6 
(A) Quantification of murine Dkk1 gene expression by qRTPCR in control or Dkk1 
overexpressing KRIB derived tumors. (B) Dkk1 does not change tumor cell proliferation 
in vitro. Proliferation of KRIB (parental) and KRIB:Dkk1 cells was analyzed with a MTS 
assay. Data are normalized in each group to values of day 1. (C) Dkk1 does not change 
tumor cell proliferation in vivo. Proliferating cells were quantified in tumors derived from 
KRIB control or KRIB:Dkk1 cells. Ki67-positive areas were determined using ImageJ 
software upon staining for Ki67 and reported to the DAPI positive areas per tumor. No 
significant (ns) difference was observed (n = 5 per group). (D) HUVEC tubulogenesis on 
Matrigel upon addition of CM derived from KRIB control or Dkk1 overexpressing cells. 
Quantification of three independent experiments (left) and representative phase contrast 
pictures (right) are shown. Error bars represent SEM and asterisks (*) indicate p values 
< 0.05. 
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Figure S7. Binding of TNC to VEGFA 
Binding of VEGFA to TNC was determined by Biacore including normalization to a blank 
surface. Binding of TNC and VEGFA to a sensorchip adsorbed with VEGFA (A) and TNC 
(B), respectively is shown. We observed that VEGFA and TNC bind to each other in a 
dose dependent manner with a Kd of 2.7 x 10-7 M (TNC binding to VEGFA) and 1.5 x 10-9 
M (VEGFA binding to TNC) which is lower than VEGFA binding to its receptor (3.3 x 10-11 
M) but is in the range of a VEGFA/glycosaminogycan interaction (2.4 x 10-8 M) (Wu et al., 
2009). 
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